WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) --

马萨诸塞州沃特敦，2025年4月9日（环球新闻社）--

Kymera Therapeutics, Inc.

凯米拉治疗公司

(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company..

(NASDAQ: KYMR)是一家临床阶段的生物制药公司，致力于推进一类用于免疫疾病的新口服小分子降解药物。今天宣布任命诺亚·古德曼（Noah Goodman），工商管理硕士，为首席商务官。古德曼先生为Kymera带来了生命科学行业的丰富多元经验，并将领导公司的业务发展战略和活动。

“We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity,” said Nello Mainolfi, Ph.D., Founder, President and CEO, Kymera Therapeutics. “Noah’s demonstrated leadership and business acumen will support Kymera’s continued growth as we advance our expanding pipeline through clinical development and eventual commercialization.”.

“我们继续专注于我们的使命，即建立一家完全集成的生物制药公司，专注于发现和开发具有生物制品样活性的口服药物，”Kymera Therapeutics创始人、总裁兼首席执行官Nello Mainolfi博士说。“诺亚展示出的领导能力和商业智慧将支持Kymera的持续增长，因为我们正在通过临床开发推进不断扩展的产品线并最终实现商业化。”

“Kymera’s approach has exceptionally broad utility with the opportunity to transform existing treatment paradigms for millions of patients suffering from debilitating diseases,” said Mr. Goodman. “I’m thrilled to join the team during such an exciting time of growth and progress and look forward to realizing the full potential and impact of our industry-leading portfolio.”.

“Kymera的方法具有异常广泛的用途，有机会改变数百万受衰弱疾病困扰患者的现有治疗模式，”古德曼先生说。“我很高兴能在这样一个增长和进步的激动人心的时期加入团队，并期待实现我们行业领先产品组合的全部潜力和影响。”

Before joining Kymera, Mr. Goodman held senior leadership roles at Chroma Medicine and nChroma Bio, serving as President and Chief Business Officer through the merger with Nvelop Therapeutics. He also served as Executive Director and Head of Business Development at Cadent Therapeutics, which was subsequently acquired by Novartis, and Seres Therapeutics, where he was responsible for leading collaborations and licensing transactions across several therapeutic areas.

在加入凯米拉之前，古德曼先生在Chroma Medicine和nChroma Bio担任高级领导职务，并在与Nvelop Therapeutics合并的过程中担任总裁兼首席商务官。他还曾担任Cadent Therapeutics的执行董事和业务发展主管，该公司后来被诺华收购，之后在Seres Therapeutics任职，负责领导多个治疗领域的合作与许可交易。

Earlier in his career, Mr. Goodman also worked in business development at Spark Therapeutics and served as a management consultant at Easton Associates, a boutique life sciences consultancy. He holds a B.S. in neuroscience from the University of Michigan and an M.B.A. from the Wharton School of the University of Pennsylvania..

早期职业生涯中，古德曼先生还曾在Spark Therapeutics从事商务拓展工作，并在精品生命科学咨询公司伊斯顿联合公司担任管理顾问。他拥有密歇根大学神经科学学士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。

About Kymera Therapeutics

关于凯米拉治疗学

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.

Kymera是一家处于临床阶段的生物技术公司，率先在靶向蛋白质降解（TPD）领域开展研究，致力于开发解决关键健康问题并有潜力显著改善患者生活的药物。Kymera正在利用TPD技术针对传统疗法无法触及的疾病靶点和通路进行研究。

Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Kymera已将首款降解剂推进至免疫疾病临床阶段，目前正专注于构建业内领先的口服小分子降解剂管线，为这些疾病的患者提供新一代便捷且高效的治疗方案。Kymera成立于2016年，过去几年一直被评为波士顿最佳工作场所之一。

For more information about our science, pipeline and people, please visit .

有关我们的科学、管道和人员的更多信息，请访问 。

www.kymeratx.com

www.kymeratx.com

or follow us on

或关注我们

X

X

or

或

LinkedIn

领英

.

。

Availability of Other Information About Kymera Therapeutics

关于凯米拉治疗学的其他信息的可用性

For more information, please visit the Kymera website at

如需更多信息，请访问 Kymera 网站

https://www.kymeratx.com/

https://www.kymeratx.com/

or follow Kymera on

或在以下平台关注 Kymera

X (@KymeraTx)

X (@KymeraTx)

and

和

LinkedIn (Kymera Therapeutics

领英 (Kymera Therapeutics)

). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on

). 投资者及其他人士应注意，Kymera通过公司网站与投资者和公众进行沟通，包括但不限于公司披露、投资者演示文稿、常见问题解答、证券交易委员会（SEC）文件以及新闻稿，此外还通过

X

X

and

和

LinkedIn

领英

. The information that Kymera posts on its website or on

。Kymera在其网站上发布的信息或在

X

X

or

或

LinkedIn

领英

could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended..

可能被视为重要信息。因此，公司鼓励投资者、媒体及其他感兴趣的人士定期查阅 Kymera 在该处发布的信息。Kymera 网站或社交媒体的内容不应被视为在《1933 年证券法》（修订版）下的任何文件中通过引用而并入。

Investor and Media Contact:

投资者和媒体联系：

Justine Koenigsberg

朱斯蒂娜·科尼格斯伯格

Vice President, Investor Relations

投资者关系副总裁

investors@kymeratx.com

投资者@kymeratx.com

media@kymeratx.com

媒体@凯美拉TX.com

857-285-5300

857-285-5300